Dr. Reddy’s (NYSE: RDY) exits Svaas Wellness unit with INR 2.23 Cr sale

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary Svaas Wellness Limited to Enspirit Technology Services Private Limited. The agreement and completion of the sale both occurred on April 7, 2026.

Svaas Wellness Limited reported turnover of Rs. 28.5 Crore in FY 2025, all from Dr. Reddy’s Laboratories Limited, representing about 0.09% of consolidated turnover. The sale consideration is INR 2.23 Cr, and Svaas Wellness Limited will cease to be a wholly owned subsidiary. The buyer is not part of the promoter group and the deal is not a related party transaction.

Key Figures

Sale consideration: INR 2.23 Cr Svaas FY 2025 turnover: Rs. 28.5 Crore Share of consolidated turnover: ~0.09% +2 more

5 metrics

Sale consideration INR 2.23 Cr Consideration for entire shareholding in Svaas Wellness Limited

Svaas FY 2025 turnover Rs. 28.5 Crore Turnover of Svaas Wellness Limited for FY 2025 audited financials

Share of consolidated turnover ~0.09% Svaas Wellness Limited turnover as percentage of consolidated turnover

Agreement date April 7, 2026 Date on which agreement for sale was entered into

Completion date April 7, 2026 Expected date of completion of sale/disposal

Key Terms

wholly owned subsidiary, Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, related party transaction, slump sale, +1 more

5 terms

wholly owned subsidiary financial

"sale of its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited"

A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.

Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

related party transaction regulatory

"The transaction does not constitute a related party transaction."

A related party transaction is any deal or transfer of value between a company and people or entities with close ties to it — such as executives, major owners, family members, or affiliated businesses. Investors watch these transactions because they can favor insiders over outside shareholders, skirt fair market pricing, or hide risks; like selling your car to a relative at a friendly price, they require clear disclosure and scrutiny to judge impact on value.

slump sale financial

"in case of a slump sale, indicative disclosures provided for amalgamation/merger"

Scheme of Arrangement regulatory

"Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement?"

A scheme of arrangement is a legal agreement between a company and its shareholders or creditors to reorganize or settle debts, often to avoid bankruptcy or make big changes. It’s like a carefully planned handshake that everyone agrees to, helping the company stay afloat or improve its financial health.

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                       Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                       No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated April 07, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: April 07, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

April 7, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124) 

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam, 

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale of wholly owned subsidiary of the Company.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended, we wish to inform that Dr. Reddy’s Laboratories Limited (“The Company”), has today, i.e. April 7, 2026, entered into an agreement for sale of its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited.

Consequent to the completion of the transaction, Svaas Wellness Limited will cease to be a wholly owned subsidiary of the Company.

The requisite details as prescribed under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as Annexure. 

This is for your information and record. 

Thanking you. 

Yours faithfully, 

For Dr. Reddy’s Laboratories Limited

K Randhir Singh 

Company Secretary, Compliance Officer, and Head-CSR 

Encl: as above 

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

Annexure

Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No	Particulars	Description
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The turnover of Svaas Wellness Limited as per FY 2025 audited financials was Rs. 28.5 Crore (100% turnover was from Dr. Reddy’s Laboratories Limited), constituting ~0.09% of the consolidated turnover.
2	Date on which the agreement for sale has been entered into	April 7, 2026
3	The expected date of completion of sale/disposal	April 7, 2026
4	Consideration received from such sale/disposal	INR 2.23 Cr
5	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Enspirit Technology Services Private Limited, having its registered office at 3-6-465, Flat 206, Legend Siddhi, Street 5, Himayathnagar, Hyderabad - 500029, Telangana, India. The buyer does not belong to Promoter / Promoter group/ group of Companies of the Company.
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	The transaction does not constitute a related party transaction. Enspirit Technology Services Private Limited is not a related party of the Company or any of its subsidiaries.
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not applicable
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

FAQ

What transaction did Dr. Reddy’s Laboratories (RDY) announce regarding Svaas Wellness Limited?

Dr. Reddy’s Laboratories agreed to sell its entire shareholding in its wholly owned subsidiary Svaas Wellness Limited to Enspirit Technology Services Private Limited. After completion, Svaas Wellness will no longer be a wholly owned subsidiary of Dr. Reddy’s Laboratories.

What is the sale consideration for Svaas Wellness Limited by Dr. Reddy’s (RDY)?

The sale consideration for Svaas Wellness Limited is INR 2.23 Cr. This amount is for Dr. Reddy’s Laboratories’ entire shareholding in the subsidiary, which will result in Svaas Wellness ceasing to be a wholly owned subsidiary upon completion.

How significant is Svaas Wellness Limited to Dr. Reddy’s (RDY) consolidated turnover?

Svaas Wellness Limited generated turnover of Rs. 28.5 Crore in FY 2025, entirely from Dr. Reddy’s Laboratories. This represented approximately 0.09% of Dr. Reddy’s consolidated turnover, indicating a relatively small contribution to overall group revenues.

When was the sale agreement for Svaas Wellness Limited signed and completed?

The agreement for sale of Svaas Wellness Limited was entered into on April 7, 2026. The expected date of completion of the sale or disposal is also April 7, 2026, indicating a same-day signing and completion timeline for this transaction.

Is the buyer of Svaas Wellness Limited related to Dr. Reddy’s (RDY) promoters or group companies?

No, the buyer, Enspirit Technology Services Private Limited, does not belong to the promoter, promoter group, or group companies of Dr. Reddy’s Laboratories. The company has also stated that the transaction does not constitute a related party transaction under applicable regulations.

Does the sale of Svaas Wellness Limited by Dr. Reddy’s involve a slump sale or scheme of arrangement?

The company has clarified that disclosures related to slump sale are not applicable, and the sale, lease, or disposal is noted as not applicable under a scheme of arrangement. Accordingly, there is no separate slump sale or scheme compliance detail attached to this transaction.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 66.9 KB